R&D Investment in New Products, New Businesses and Core Technologies
First written in FY2016. 13 of 33 entries say "Restated". Latest entry: 2026-07-02.
115 other companies' latest entry also says "Advanced".
- 2026-07-02AdvancedShare Issuance and Disposal
「Approximately ¥30.5 billion is scheduled to be allocated to R&D expenses for developing physical AI, investments and loans to expand alliances, and funds for repaying borrowings or redeeming bonds.」
Presented specific funding of approximately ¥30.5 billion for R&D expenses related to physical AI and investments and loans to expand alliances. - FY2026Higher research and development expensesAnnual report
「R&D expenses for the consolidated fiscal year were ¥56.8 billion. The main R&D activities and expenses for each business segment are as follows.」
R&D expenses increased from ¥53.3 billion in the previous fiscal year to ¥56.8 billion. The company is expanding into physical AI, hydrogen aircraft, hydrogen compressors, CO2 separation and capture, and medical and social robots. - FY2026-H1R&D expenses of ¥27.2 billionAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the six-month consolidated period was ¥27.2 billion.」
The company disclosed R&D expenses of ¥27.2 billion for the six-month consolidated period and explained that there were no material changes in the status of its R&D activities. - FY2025-H1R&D expenses of ¥26.1 billionAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the six-month consolidated period was ¥26.1 billion.」
The company disclosed R&D expenses of ¥26.1 billion for the six-month consolidated period and explained that there were no material changes in the status of its R&D activities. - FY2024Higher research and development expensesAnnual report
「R&D expenses for the consolidated fiscal year were ¥53.3 billion. The main R&D activities and expenses for each business segment are as follows.」
R&D expenses increased from ¥50.7 billion in the previous fiscal year to ¥53.3 billion. R&D activities in hydrogen, AI and digital technologies, medical and logistics robots, electrification and hybridization, and hydrogen aircraft were described. - FY2024-Q3Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥36.6 billion.」
R&D expenses for the third quarter cumulative period were ¥36.6 billion, up from ¥33.8 billion in the same period of the previous year. The company explained that there were no material changes in the status of its R&D activities. - FY2024-Q2Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥23.6 billion.」
R&D expenses for the second quarter cumulative period were ¥23.6 billion, up from ¥22.0 billion in the same period of the previous year. The company explained that there were no material changes in the status of its R&D activities. - FY2024-Q1R&D expenses of ¥11.3 billionAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥11.3 billion.」
The company disclosed R&D expenses of ¥11.3 billion for the first quarter cumulative period and explained that there were no material changes in the status of its R&D activities. - FY2023Higher R&D expenses and expansion of priority areasAnnual report
「R&D expenses for the consolidated fiscal year were ¥50.7 billion. The main R&D activities and expenses for each business segment are as follows.」
R&D expenses increased from ¥47.0 billion in the previous fiscal year to ¥50.7 billion. R&D activities in the hydrogen supply chain, hydrogen aircraft, electrification, medical and logistics robots, DX and CCUS were described. - FY2023-Q3Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥33.8 billion.」
R&D expenses for the third quarter cumulative period were ¥33.8 billion, up from ¥31.7 billion in the same period of the previous year. The company explained that there were no material changes in the status of its R&D activities. - FY2023-Q2Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥22.0 billion.」
R&D expenses increased from ¥19.8 billion in the same period of the previous year to ¥22.0 billion. The company explained that there were no material changes in the status of its R&D activities. - FY2023-Q1Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥10.7 billion.」
R&D expenses increased from ¥8.8 billion in the same period of the previous year to ¥10.7 billion. The company explained that there were no material changes in the status of its R&D activities. - FY2022Higher R&D expenses and expansion of priority areasAnnual report
「R&D expenses for the consolidated fiscal year were ¥47.0 billion. The main R&D activities and expenses for each business segment are as follows.」
R&D expenses increased from ¥44.9 billion in the previous fiscal year to ¥47.0 billion. The company expanded its priority areas to include the hydrogen supply chain, hydrogen aircraft, electrification, medical and logistics robots, and CCUS. - FY2022-Q3Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥31.7 billion.」
R&D expenses increased from ¥29.7 billion in the same period of the previous year to ¥31.7 billion. The company explained that there were no material changes in the status of its R&D activities. - FY2022-Q2Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥19.8 billion.」
R&D expenses increased by ¥0.8 billion, from ¥19.0 billion in the same period of the previous year to ¥19.8 billion. The company explained that there were no material changes in the status of its R&D activities. - FY2022-Q1Higher research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥8.8 billion.」
R&D expenses increased from ¥8.1 billion in the same period of the previous year to ¥8.8 billion. The company explained that there were no material changes in the status of its R&D activities. - FY2021-Q3Continued decline in research and development expensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥29.7 billion. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
The company stated that there were no material changes in the status of its R&D activities, while R&D expenses decreased from ¥36.3 billion in the same period of the previous year to ¥29.7 billion. - FY2021-Q2Decline in R&D ExpensesAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥19.0 billion. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
The company stated that there were no material changes in the status of its R&D activities, while R&D expenses decreased from ¥23.7 billion in the same period of the previous year to ¥19.0 billion. - FY2021-Q1RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥8.1 billion. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
R&D activities continued, with R&D expenses of ¥8.1 billion recorded for the first quarter cumulative period. The company explained that there were no material changes in the status of these activities. - FY2020-Q3RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥36.3 billion. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥36.3 billion for the third quarter cumulative period. - FY2020-Q2RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥23.7 billion. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
R&D activities continued, with R&D expenses of ¥23.7 billion recorded for the second quarter cumulative period. The company explained that there were no material changes in the status of these activities. - FY2020-Q1RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥11.1 billion. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
R&D activities continued, with R&D expenses of ¥11.1 billion recorded for the first quarter cumulative period. The company explained that there were no material changes in the status of these activities. - FY2019AdvancedAnnual report
「R&D expenses for the consolidated fiscal year were ¥48.7 billion. The main R&D activities and expenses for each business segment are as follows.」
R&D expenses increased from ¥43.6 billion in the previous fiscal year to ¥48.7 billion. Specific R&D activities in hydrogen, ICT and IoT, aircraft engines, robots and medical robots were described. - FY2019-Q3RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥33.4 billion. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
R&D activities continued, with R&D expenses of ¥33.4 billion recorded for the third quarter cumulative period. The company explained that there were no material changes in the status of these activities. - FY2019-Q2RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥21.2 billion. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
R&D activities continued, with R&D expenses of ¥21.2 billion recorded for the second quarter cumulative period. The company explained that there were no material changes in the status of these activities. - FY2019-Q1RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥10.3 billion. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
R&D activities continued, with R&D expenses of ¥10.3 billion recorded for the first quarter cumulative period. The company explained that there were no material changes in the status of these activities. - FY2018-Q3RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥31.0 billion. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
The company recorded R&D expenses of ¥31.0 billion and explained that there were no material changes in the status of its R&D activities. - FY2018-Q2RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥20.6 billion. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
The company recorded R&D expenses of ¥20.6 billion and explained that there were no material changes in the status of its R&D activities. - FY2018-Q1RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥9.4 billion. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
The company recorded R&D expenses of ¥9.4 billion and explained that there were no material changes in the status of its R&D activities. - FY2017-Q3RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the third quarter cumulative period was ¥30.8 billion. There were no material changes in the status of the Group's R&D activities during the third quarter cumulative period.」
The company reported R&D expenses of ¥30.8 billion and explained that there were no material changes in the status of its R&D activities. - FY2017-Q2RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the second quarter cumulative period was ¥20.6 billion. There were no material changes in the status of the Group's R&D activities during the second quarter cumulative period.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥20.6 billion for the second quarter cumulative period. - FY2017-Q1RestatedAnnual report
「The amount of R&D activity undertaken by the Group as a whole during the first quarter cumulative period was ¥9.4 billion. There were no material changes in the status of the Group's R&D activities during the first quarter cumulative period.」
R&D activities continued, with R&D expenses of ¥9.4 billion recorded for the first quarter cumulative period. The company explained that there were no material changes in the status of these activities. - FY2016First statedAnnual report
「R&D expenses for the consolidated fiscal year were ¥43.6 billion. The main R&D activities and expenses for each business segment are as follows.」
R&D expenses were ¥43.6 billion. The business divisions and the head office's Technology Development Division jointly developed new products and businesses, core technologies, and hydrogen-related equipment and systems.